{
    "organizations": [],
    "uuid": "32f26633f5a5b3815b998d1a8c3c50e641a5b287",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-neogenomics-reports-q4-adjusted-ep/brief-neogenomics-reports-q4-adjusted-eps-of-0-05-idUSASB0C6M8",
    "ord_in_thread": 0,
    "title": "BRIEF-NeoGenomics Reports Q4 Adjusted EPS Of $0.05",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 21 (Reuters) - NeoGenomics Inc:\n* NEOGENOMICS REPORTS REVENUE OF $67.8 MILLION ON 18.7% CLINICAL VOLUME GROWTH AND $10.5 MILLION OF ADJUSTED EBITDA IN THE FOURTH QUARTER OF 2017\n* Q4 ADJUSTED EARNINGS PER SHARE $0.05 * Q4 REVENUE ROSE 12.1 PERCENT TO $67.8 MILLION * SEES FY 2018 REVENUE $260 MILLION TO $272 MILLION * SEES 2018 ‍GAAP DILUTED EPS TO BE A LOSS OF $0.13 TO $0.08 PER SHARE​\n* SEES 2018 ‍ADJUSTED DILUTED EPS TO BE $0.15 - $0.20 PER SHARE​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-21T20:10:00.000+02:00",
    "crawled": "2018-02-22T17:58:47.029+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "neogenomics",
        "inc",
        "neogenomics",
        "report",
        "revenue",
        "million",
        "clinical",
        "volume",
        "growth",
        "million",
        "adjusted",
        "ebitda",
        "fourth",
        "quarter",
        "q4",
        "adjusted",
        "earnings",
        "per",
        "share",
        "q4",
        "revenue",
        "rose",
        "percent",
        "million",
        "see",
        "fy",
        "revenue",
        "million",
        "million",
        "see",
        "diluted",
        "eps",
        "loss",
        "per",
        "see",
        "diluted",
        "eps",
        "per",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}